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Objectives:  We  assessed  angioscopic  ﬁndings  after  everolimus-eluting  stents  (EES)  implantation,  com-
pared  with  sirolimus-eluting  stents  (SES).
Background:  Coronary  angioscopy  (CAS)  provides  an  opportunity  to assess  neointimal  coverage  over stent
struts, thrombus,  and  plaque  color  by direct  visualization.  CAS  is  a useful  tool  for evaluating  stent  struts
after  drug-eluting  stent  implantation.  Angioscopic  ﬁndings  after  EES implantation  have  not  been reported
before.
Methods:  We  performed  CAS  in 23  patients  who  were  treated  with  EES  and  41  patients  with  SES. CAS
was  performed  8.5 months  after  stent  implantation.  We  assessed  neointimal  coverage,  thrombus,  and
plaque color.  We  classiﬁed  neointimal  coverage  in 4  grades:  grade  0 =  struts  were  completely  exposed;
grade  1  =  struts  were  visible  with  dull  light  reﬂexion;  grade  2  = there  was  no  light  reﬂexion  from  slightly
visible  struts;  grade  3 =  struts  were  completely  covered.
Results:  There  was  no  signiﬁcant  difference  in  minimum,  maximum,  dominant  grade  of neointimal  cov-
erage,  and  heterogeneity  index  between  EES  and  SES.  Thrombus  was  less  frequently  observed  in  EES than
SES (4%  vs  29%,  p = 0.02).  When  we  divided  study  patients  into  acute  coronary  syndrome  (ACS)  or  stable
angina  pectoris  (SAP),  there  was  a tendency  toward  less  thrombus  in  EES than SES,  in both  ACS  and  SAP.
Maximum  color  grade  of  the  plaques  was  less  advanced  in  EES  than  SES (p < 0.01).  Yellow  plaques  of
grade  2  or  3  were  less  frequent  in EES  than  SES  (35%  vs  76%,  p  <  0.01).
Conclusions:  This  study  suggested  that  EES  were  associated  with  lower  risk  of  thrombus  formation  than
2  Jap
SES.
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Drug-eluting stents (DES) have dramatically reduced the risk
f restenosis and target vessel revascularization (TVR) compared
ith bare metal stents (BMS) [1–3]. As ﬁrst-generation DES were
sed widely around the world, the raised concern was  the increased
isk of late stent thrombosis after ﬁrst-generation DES implantation
4,5]. Second-generation DES have been designed with the goal of
mproving safety, efﬁcacy, and device performance.Everolimus-eluting stents (EES) are one of the second-
eneration DES that have biocompatible ﬂuoropolymer coating
n an open cell, thin-strut ﬂexible cobalt–chromium stent.
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ttp://dx.doi.org/10.1016/j.jjcc.2012.08.011anese  College  of Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
Previous clinical studies have demonstrated favorable clinical out-
comes of patients treated with EES [6–9]. Preclinical study showed
that EES were associated with a less inﬂammatory reaction com-
parable with that of BMS  [10]. Coronary angioscopy (CAS) has been
shown to be useful for the assessment of stent status, because it
permits direct visualization of the target. However, no previous
study reported angioscopic ﬁndings after EES implantation. In this
study, we  undertook coronary angioscopic examination 9 months
after EES implantation, and compared the ﬁndings with those of
sirolimus-eluting stents (SES).
Methods
Study patientsThis study consisted of 23 patients who  underwent percuta-
neous coronary intervention (PCI) with EES and 41 patients who
underwent angioplasty with SES (Cypher BX, Cordis, Miami, FL,
vier Ltd. All rights reserved.
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Fig. 1. Angioscopic grading of neointimal stent strut coverage. Grade 0: stent struts with complete exposure (similar to immediately after implantation). Grade 1: transparent
stent  struts with dull light reﬂexion. Grade 2: stent struts slightly visible, with no light reﬂexion from stent struts. Grade 3: stent struts were completely covered, and not
seen  through neointima.
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SA). CAS was performed 8.5 ± 2.3 months after EES implantation
nd SES implantation. Patients in EES group were enrolled from
ctober 2010 to December 2011 and patients in SES group were
nrolled from April 2005 to February 2008. Left main disease, ostial
esion, and tortuous vessels were excluded because of the expected
ifﬁculty in acquiring the angioscopic images for the whole stented
egments. When we implanted more than one stent, we described
he sum of the lengths of all the stents we implanted.Informed consent was obtained from each patient and this pro-
ocol was reviewed and approved by the ethical committee of
iroshima City Hospital.
able 1
rocedural Characteristics and serial changes in quantitative coronary angiography data.
Variables EES (n = 23)
Stent diameter (mm)  3.0 ± 0.4 
Stent length (mm)  24.1 ± 14.0 
Maximum inﬂation pressure (atm) 18 ± 5 
Total inﬂation time (min) 2.4 ± 1.3 
Direct stent 3 (13%) 
Quantitative coronary angiography
Pre-intervention
Reference diameter (mm)  2.60 ± 0.46 
Minimal lumen diameter (mm)  0.17 ± 0.42 
Diameter stenosis (%) 72.4 ± 13.2 
Post-intervention
Minimal lumen diameter (mm) 2.62 ± 0.51 
Diameter stenosis (%) 5.4 ± 10.3 
Follow-up
Minimal lumen diameter (mm)  2.46 ± 0.46 
Diameter stenosis (%) 10.4 ± 13.1 
In-stent late loss (mm) 0.71 ± 0.38 
ES, everolimus-eluting stents; SES, sirolimus-eluting stents.ed as 0 (white), 1 (light yellow), 2 (yellow), 3 (bright yellow).
Angioscopic examination procedure
Catheterization was  performed with a radial approach using
6F catheters. After 5000 units of heparin administration, selec-
tive coronary angiography was  performed. Coronary angioscopic
examination was performed with the angioscope VFS-1300 (Nihon
Kohden, Tokyo, Japan) and optical ﬁber IF-783V (Nihon Kohden).
The outer section of the 4F probing catheter (USCI, Billerica, MA,
USA) was used as the guide to insert the optical ﬁber into the
coronary artery. The angioscopic observations were made while
the blood was cleared away from the view by the injection of 3%
SES (n = 41) p Value
3.1 ± 0.3 0.20
23.8 ± 8.9 0.91
17 ± 2 0.56
2.1 ± 0.7 0.22
22 (54%) <0.01
2.90 ± 0.48 0.02
0.15 ± 0.35 0.01
63.7 ± 17.1 0.04
2.73 ± 0.31 0.30
3.9 ± 14.9 0.67
2.59 ± 0.38 0.24
9.3 ± 15.6 0.78
1.04 ± 0.48 0.84
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Table 2
Clinical and lesion characteristics.
Variables EES (n = 23) SES (n = 41) p Value
Time to coronary angioscopy 9.1 ± 2.0 8.1 ± 2.4 0.11
Age 66.2 ± 11.0 68.1 ± 8.5 0.46
Men 18  (78%) 29 (71%) 0.57
Hypertension 19 (83%) 28 (68%) 0.25
Diabetes mellitus 8 (35%) 13 (32%) 1.00
Hyperlipidemia 15 (65%) 26 (63%) 1.00
Current smoking 3 (13%) 16 (39%) 0.04
Lesion location
LAD 8(35%) 26 (63%) 0.04
LCX 6 (0.26%) 5(12%) 0.18
RCA  9 (39%) 10 (25%) 0.26
Type B2/C lesionsa 16 (70%) 39 (95%) 0.01
ACS  9 (39%) 23 (56%) 0.30
Medications at follow-up
Dual antiplatelet therapy 23 (100%) 41 (100%) 1.00
-Blockers 9 (39%) 19 (46%) 0.61
ACEI/ARB 17 (74%) 30 (73%) 1.00
Calcium blockers 13 (57%) 14 (34%) 0.11
Nitrates 2 (9%) 4 (10%) 1.00
Nicorandil 2 (9%) 2 (5%) 0.61
Statins 21 (91%) 31 (76%) 0.18
EES, everolimus-eluting stents; SES, sirolimus-eluting stents; LAD, left anterior descending artery; LCX, left circumﬂex artery; RCA, right coronary artery; ACS, acute coronary
syndrome; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
a Based on American College of Cardiology/American Heart Association classiﬁcation.
Fig. 3. Distribution of neointimal coverage (all patients). Among all patients, there was  no signiﬁcant difference in minimum (p = 0.21), maximum (p = 0.21), or dominant
grade  (p = 0.74) of neointimal coverage, and heterogeneity index (p = 0.19) between everolimus-eluting stents (EES) and sirolimus-eluting stents (SES).
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Fig. 4. Distribution of neointimal coverage [acute coronary syndrome (ACS) group]. Among ACS group, there was no signiﬁcant difference in minimum (p = 0.26), maximum
( dex (p
d
[
E
o
t
(
t
i
r
w
c
a
m
H
m
a
[
(
p
pp  = 0.84), or dominant grade (p = 0.82) of neointimal coverage, and heterogeneity in
extran-40 through the probing catheter as previously reported
11]. Angioscopy images were recorded on a digital recorder.
valuation of angioscopic ﬁndings
We  assessed neointimal coverage over stent struts, the existence
f red or white thrombus, and plaque color grade. We  classiﬁed
he degree of neointimal coverage over the stent struts in 4 grades
Fig. 1) as previously described [11]. In brief: grade 0 = stent struts
hat were completely exposed (similar to immediately after the
mplantation); grade 1 = stent struts were visible with dull light
eﬂexion; grade 2 = there was no light reﬂexion from the stent struts
ith slightly visible struts; grade 3 = stent struts were completely
overed, and not seen through the neointima. Neointimal cover-
ge was evaluated in the entire stented segments. We assessed
inimum, maximum, and dominant neointimal coverage grade.
eterogeneity index was deﬁned by subtracting the minimum from
aximum grade. Thrombus was deﬁned on the basis of the criteria
dopted by the European Working Group on Coronary Angioscopy
12]. The plaque color under the stent was graded as 0 (white), 1
light yellow), 2 (yellow), 3 (bright yellow) compared with the sam-
le colors presented in Fig. 2 [13]. The maximum color grade of the
laques was assessed. Angioscopic evaluations were made by two = 0.75) between everolimus-eluting stents (EES) and sirolimus-eluting stents (SES).
angioscopic specialists blinded to the clinical status. This study was
performed in a single center.
Quantitative coronary angiography
Quantitative coronary angiography was performed using Cen-
tricity Cardiology CA1000 Cardiac Review 1.0 (Spa10) Operating
System (GE Healthcare, Little Chalfont, UK) before stenting, imme-
diately after stenting, and also at follow-up with the same angle
of projection (Table 1). Measurements were performed in end-
diastole, preferably in 2 orthogonal projections or, if this could not
be obtained, in the projection that best showed the diseased seg-
ment with as little foreshortening as possible. Reference diameter
(millimeters), minimal lumen diameter (millimeters), and lumen
diameter stenosis (%) were measured after thrombus aspiration in
patients with acute coronary syndrome and before PCI in patients
with stable angina pectoris.
Statistical analysisContinuous variables were shown as mean ± SD and analyzed
by the Student’s t test. Categorical variables were expressed as fre-
quencies and analyzed by chi-square statistics or Fisher exact test.
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Fig. 5. Distribution of neointimal coverage [stable angina pectoris (SAP) group]. Among the SAP group, maximum grade and heterogeneity index were less advanced in
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(verolimus-eluting stents (EES) than sirolimus-eluting stents (SES) (p < 0.05).
e  used the JMP  statistical package (version 5.0.1 J, SAS Institute,
ary, NC, USA) for all statistical tests. A signiﬁcance level of 0.05
as used and 2-tailed tests were applied.
esults
aseline characteristics
Baseline clinical characteristics of patients are shown in
ables 1 and 2. CAS was performed 9.1 ± 2.0 months after EES
mplantation and 8.1 ± 2.4 months after SES implantation. All
atients were on dual antiplatelet therapy at the time of angio-
copic examination. There was no signiﬁcant difference in the
umber of stents between EES and SES (1.2 ± 0.5 vs 1.1 ± 0.3,
 = 0.44). In 2 patients with EES and 4 patients with SES, 2 stents
ere implanted. In 1 patient with EES, 3 stents were implanted. The
emaining 57 patients were treated with single stent implantation.
ngioscopic ﬁndingsDistribution of neointimal coverage is shown in Figs. 3–5.  There
as no signiﬁcant difference in minimum (p = 0.34), maximum
p = 0.11), or dominant grade (p = 0.74) of neointimal coverage, andheterogeneity index (p = 0.14) between EES and SES. Maximum
color grade of the plaques was  less advanced in EES than SES
(p < 0.01). Yellow plaques of grade 2 or 3 were less frequent in EES
than SES (35% vs 76%, p < 0.01) (Fig. 6). Among 41 patients with
SES, 12 patients (29%) were found to have thrombus: red thrombus
in 8 patients, white thrombus in 2 patients, and both thrombus
in 2 patients. In patients treated with SES, most thrombus was
observed at the site of yellow plaques (86%). On the contrary, among
23 patients with EES, only 1 patient (4%) was found to have red
thrombus at the site of yellow plaques (Fig. 7). The difference in
the incidence of thrombus between EES and SES reached statistical
signiﬁcance (p = 0.02). Representative cases are shown in Fig. 8.
The study patients were divided into acute coronary syndrome
(ACS) or stable angina pectoris (SAP) and angioscopic ﬁndings were
compared between EES and SES. In the ACS group, there was  no sig-
niﬁcant difference in neointimal coverage grade and heterogeneity
index (Fig. 4). In the SAP group, maximum grade was lower and
heterogeneity index was  smaller in EES than SES (p < 0.05) (Fig. 5).
Maximum color grade of the plaques tended to be less advanced
in EES than SES in both ACS group and SAP group (Fig. 6). There
was a tendency toward less thrombus in EES than SES, in both
ACS group (0% vs 35%, p = 0.07) and SAP group (7% vs 22%, p = 0.35)
(Fig. 7).
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Fig. 6. Maximum color grade of the plaques. Maximum color grade of the plaques was less advanced in everolimus-eluting stents (EES) than sirolimus-eluting stents (SES)
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iscussion
In this study, there was no signiﬁcant difference in minimum,
aximum, or dominant grade of neointimal coverage, and hetero-
eneity index between EES and SES. Thrombus was less frequently
bserved in EES than SES (4% vs 29%, p = 0.02). Maximum color grade
f the plaques was less advanced in EES than SES. Yellow plaques
f grade 2 or 3 were less frequent in EES than SES.
Several clinical studies have shown clinical efﬁcacy and safety of
ES. SPIRIT IV Trial (Clinical Evaluation of the XIENCE V Everolimus
luting Coronary Stent System) was a prospective, multicenter, ran-
omized, single-blind clinical trial in which 3690 patients were
andomly assigned to receive EES or paclitaxel-eluting stents (PES).
t reported that EES were associated with lower 1-year rates of
arget-lesion failure, myocardial infarction, and stent thrombosis,
ompared with PES [6].  Cassese et al. performed a meta-analysis
f randomized clinical studies to assess the EES vs PES or SES
afety and efﬁcacy, among 8058 patients undergoing PCI, at 12-
onth follow-up [8,9]. They reported that EES were associated with
igniﬁcantly lower target-lesion revascularization and myocardial
nfarction than PES or SES. A trend toward lower stent thrombosis
ates in favor of EES vs PES or SES was found.
Using optical coherence tomography (OCT), Inoue et al. reported
hat most EES struts were covered with uniform and thin neointima, p < 0.01). Maximum color grade of the plaques tended to be less advanced in EES
roup (Fig. 6).
and no thrombus was  detected [14]. OCT as well as intravascu-
lar ultrasound, however, is seeing only shadow of the target. CAS
is a different kind of intracoronary imaging modality that can
assess the surface color and superﬁcial morphology of plaque,
thrombus, and stent struts by direct visualization. Previous stud-
ies have demonstrated the usefulness of CAS as an intracoronary
imaging modality to assess the stent status [15,16].  It has been
shown that the chronic angioscopic ﬁndings are different not only
between BMS  and DES, but also among SES, PES, and zotarolimus-
eluting stents [17–19].  However, angioscopic ﬁndings after EES
implantation remain unknown. This is the ﬁrst study that assessed
angioscopic ﬁndings after EES implantation.
In this study, there was no signiﬁcant difference in the max-
imum and minimum coverage over stent struts, suggesting that
both EES and SES effectively suppressed neointimal proliferation.
Previous studies have suggested that poor neointimal coverage is
associated with thrombus formation after DES implantation [20].
In this study, we observed thrombus in 29% of patients treated with
SES even 8 months after SES implantation. However, only 1 patient
(4%) with EES was found to have red thrombus, which was signiﬁ-
cantly different from SES. These ﬁndings suggest that factors other
than poor neointimal coverage contribute to thrombus formation.
Using CAS, Higo et al. reported that the maximum yellow color
grade of the neointima within DES-implanted lesions increased
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Fig. 7. Incidence of thrombus formation. Thrombus was  less frequently observed in everolimus-eluting stents (EES) than sirolimus-eluting stents (SES) (4% vs 29%, p = 0.02)
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imong all patients. Among 41 patients with SES, 12 patients (29%) were found to hav
n  2 patients. Among 23 patients with EES, only 1 patient (4%) was found to have 
cute  coronary syndrome (ACS) group (0% vs 35%, p = 0.07) and the stable angina pe
igniﬁcantly from baseline to follow-up [21]. Importantly, the
revalence of thrombus was signiﬁcantly higher on the yellow
han on the white neointimal areas, and thrombus was  detected
n yellow and/or grade-0 or 1 neointima, but never on the white
rade-2 neointima. These ﬁndings suggested that yellow plaque is
ontributory to thrombus formation after SES implantation as well
s poor neointimal coverage. The current study showed that yel-
ow plaques were less frequently observed in EES than SES. This
ay  be contributory to less thrombus formation after EES implan-
ation. It has been reported that coronary endothelial function
as impaired after DES implantation and the coronary functional
bnormalities may  be associated with adverse outcomes in patients
ndergoing angioplasty with DES [22]. Higo et al. reported that
mpaired re-endothelialization after SES implantation might lead to
he formation of the newly atherosclerotic lesions, which could be
bserved as yellow color plaques by CAS [21]. A lower incidence of
ellow color plaques assessed by angioscopy after EES implantation
ay  reﬂect preserved endothelial function.
tudy limitationsFirst, the major limitation of this study is small sample size,
ecause of the invasive nature of angioscopic study. A multi-center
egistry will be necessary to assess coronary angioscopic ﬁndings
n a substantial number of patients. When we divided these studymbus: red thrombus in 8 patients, white thrombus in 2 patients, and both thrombus
rombus. There was  a tendency toward less thrombus in EES than SES, in both the
 (SAP) group (7% vs 22%, p = 0.35).
patients into ACS or SAP, there was  a tendency toward less throm-
bus in EES than SES, in both the ACS group (0% vs 35%, p = 0.07) and
the SAP group (7% vs 22%, p = 0.35). The difference did not reach sta-
tistical signiﬁcance because of the small number of study patients.
Second, the serial changes of thrombus and the plaque color grade
were not assessed since coronary angioscopic examination was not
performed at the time of PCI. Third, because of difﬁculties to use
multiple modalities for diagnostic catheterization, simultaneous
assessment of plaque volume, plaque composite, or endothelial
function was not performed. Fourth, which type of stent would be
implanted at PCI depended on physicians’ decision. There might be
a possibility of selection bias. Fifth, left main disease, ostial lesion,
and tortuous vessels were excluded because of the expected difﬁ-
culty in acquiring the angioscopic images for the whole stented
segments. Angioscopic examination was  tried, but was not suc-
cessful in 2 patients with EES and 5 patients with SES, because
coronary angioscopic catheter did not cross target lesions. These
patients were excluded from this study. In 64 patients included in
this study, however, good angioscopic images were obtained. Sixth,
the follow-up duration was one month longer in the EES group than
the SES group, although the difference did not reach statistical sig-
niﬁcance. Seventh, it was uncertain whether in-stent thrombus,
which was detected by angioscopy, would develop in to clinical
events in the future. Although thrombus was not directly linked
to clinical events, presenting of thrombus may  be a risk of stent
K. Dai et al. / Journal of Cardiology 61 (2013) 22–30 29
Fig. 8. Representative cases: angioscopic ﬁndings 8 months after everolimus-eluting stent implantation in a patient with acute myocardial infarction and 1 year after
sirolimus-eluting stent implantation in a patient with acute myocardial infarction. (A) A 62-year-old man  with acute myocardial infarction was  treated with everolimus-
eluting stent (3.0 × 15 mm)  implantation in the proximal left circumﬂex artery. Eight months after stent implantation, coronary angiography showed no restenosis. Coronary
angioscopic images were shown above. Neointimal coverage was graded as grade 0 at the proximal and distal portion and grade 1 at the mid portion of the stent. Color grade
of  the plaques was  graded as grade 0. (B) A 72-year-old man  with acute myocardial infarction was  treated with sirolimus-eluting stent (3.5 × 18 mm)  implantation in the
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t  the proximal portion of the stent, neointimal coverage was graded as grade 0. R
overage was  grade 1, and white thrombus was  observed adhered on the yellow pl
hrombosis. Larger-scale studies are necessary to conﬁrm these
ndings.
onclusions
This study suggested that EES were associated with lower risk
f thrombus formation than SES.
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